Rim Ishak, MD
Allergy & Immunology · Lorain, OHNPI 1255836409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,870 of the $3,895 with a category attached, or 73.7%. 8 manufacturers reported payments, led by Regeneron at 25.7% of the total. Reporting peaked in 2022 at $2,018 and has fallen 89.8% since, to $205 in 2025.
Across 39 payments — averaging $99.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1K
- Regeneron Healthcare Solutions, Inc.$695
- AstraZeneca$659
- GSK$547
- Aerin Medical Inc.$362
- Sanofi$271
- plus $361 from 2 others
What the payments were for
- Grants$1,00026%
- Food & beverage$2,87074%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $1,000 |
| Regeneron Healthcare Solutions, Inc. | 8 | $695 |
| AstraZeneca | 7 | $659 |
| GSK | 5 | $547 |
| Aerin Medical Inc. | 5 | $362 |
| Sanofi | 2 | $271 |
| Amgen | 10 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $107 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$882
- NUCALA$351
- TEZSPIRE$231
- CUVITRU$107
- VIVAER STYLUS$104
- RHINAER STYLUS$104
How this compares
$3,895 in reported general payments places this provider in the 55th percentile of 128 allergy & immunology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $45,687 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,205 |
| Epinephrine | 16 | $3,148 |
| Azelastine Hcl | 50 | $1,383 |
| Fluticasone Propionate | 100 | $1,202 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $786 |
| Ipratropium Bromide | 28 | $727 |
| Montelukast Sodium | 20 | $252 |
| Famotidine | 15 | $132 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Lorain
- Justin GreiweCincinnati$1M
- Jonathan BernsteinCincinnati$810K
- Adam UpdegraffToledo$379K
- Syed RehmanToledo$374K
- Gordon MyersCincinnati$346K
- Nancy Wasserbauer KingstonRocky River$256K
- David LangCleveland$251K
- James FernandezCleveland$179K
- Donald McNeilColumbus$136K
- Amber PattersonFindlay$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.